Coratti A, Fernandes E, Lombardi A, Di Marino M, Annecchiarico M, Felicioni L, Giulianotti P C
Department of General Surgery, Misericordia Hospital, Grosseto, Italy.
Kings College Hospital, London, UK.
Eur J Surg Oncol. 2015 Aug;41(8):1106-13. doi: 10.1016/j.ejso.2015.01.014. Epub 2015 Feb 23.
Robot-assisted surgery for the treatment of gastric cancer is considered to be safe and feasible with early post-operative outcomes comparable to open and laparoscopic series. However, data regarding long-term oncological outcomes are lacking. Aim of this study is to evaluate long-term oncological outcomes of a cohort of gastric cancer patients treated surgically with the robot-assisted approach.
A prospectively collected database of robot-assisted gastrectomies performed for gastric cancer at the 'Misericordia Hospital' between September 2001 and October 2011 was retrospectively analysed. Data regarding surgical procedures, early postoperative course, and long-term follow-up were analysed.
The study included 98 consecutive robot-assisted gastrectomies. Fifty-nine distal gastrectomies, 38 total gastrectomies, and 1 proximal gastrectomy. Open conversion occurred in seven patients (7.1%) due to locally advanced disease. Postoperative morbidity and mortality were 12.2% and 4.1% respectively. Post-operative staging showed 46 patients (46.9%) with stage I disease, 25 patients (25.5%) with stage II, 26 (26.5%) with stage III and 1 (1.02%) with stage IV. The mean follow-up was 46.9 months. Cumulative 5-year overall survival (OS) was 73.3% (95% CI: 62.2-84.4). Five-year survival by stage subgroups was 100% for patients with stage IA, 84.6% for stage IB, 76.9% for stage II, and 21.5% for stage III. The only patient in stage IV of this series died eight months after surgery.
Robot-assisted gastrectomy for the treatment of gastric cancer is safe and feasible. It provides long-term outcomes comparable to most open and laparoscopic series. Further studies are necessary to better define its indication.
机器人辅助手术治疗胃癌被认为是安全可行的,术后早期结果与开放手术和腹腔镜手术系列相当。然而,关于长期肿瘤学结果的数据尚缺乏。本研究的目的是评估一组接受机器人辅助手术治疗的胃癌患者的长期肿瘤学结果。
回顾性分析了2001年9月至2011年10月在“慈悲医院”为胃癌进行的机器人辅助胃切除术的前瞻性收集数据库。分析了有关手术程序、术后早期过程和长期随访的数据。
该研究包括98例连续的机器人辅助胃切除术。其中59例远端胃切除术,38例全胃切除术,1例近端胃切除术。7例患者(7.1%)因局部晚期疾病转为开放手术。术后发病率和死亡率分别为12.2%和4.1%。术后分期显示,46例患者(46.9%)为I期疾病,25例患者(25.5%)为II期,26例(26.5%)为III期,1例(1.02%)为IV期。平均随访时间为46.9个月。5年累积总生存率(OS)为73.3%(95%CI:62.2-84.4)。按分期亚组的5年生存率,IA期患者为100%,IB期为84.6%,II期为76.9%,III期为21.5%。该系列中唯一的IV期患者术后8个月死亡。
机器人辅助胃切除术治疗胃癌是安全可行的。它提供了与大多数开放手术和腹腔镜手术系列相当的长期结果。需要进一步研究以更好地确定其适应症。